Radiotherapy-synergized in situ hydrogel vaccine with engineered Lactococcus lactis FOLactis potentiates anti-tumor immunity in pancreatic cancer - Takeaways - MDSpire

Radiotherapy-synergized in situ hydrogel vaccine with engineered Lactococcus lactis FOLactis potentiates anti-tumor immunity in pancreatic cancer

  • By

  • Jingjing Chen

  • Qiaoli Wang

  • Junmeng Zhu

  • Xinyuan Bai

  • Haochen Tang

  • Xiang Kong

  • Lu Zou

  • Qinghua Zheng

  • Yingxin Wang

  • Yan Zhao

  • Baorui Liu

  • Fanyan Meng

  • Juan Du

  • June 29, 2026

  • 0 min

Share

  • 1

    The study developed an in situ hydrogel vaccine, Gel-FOLactis, to enhance anti-tumor immune responses in pancreatic cancer.

  • 2

    Gel-FOLactis combines engineered Lactococcus lactis with radiotherapy to improve antigen presentation and T cell activation.

  • 3

    The hydrogel enables sustained release of immune-stimulating cytokines Flt3L and OX40L, enhancing dendritic cell function.

  • 4

    The combination therapy effectively transforms the immunosuppressive tumor microenvironment from 'cold' to 'hot'.

  • 5

    Results indicate that RH-FOLactis significantly boosts anti-tumor immune responses and tumor eradication in pancreatic cancer models.

Original Source(s)

Radiotherapy-synergized in situ hydrogel vaccine with engineered Lactococcus lactis FOLactis potentiates anti-tumor immunity in pancreatic cancer

  • by Jingjing Chen, Qiaoli Wang, Junmeng Zhu, Xinyuan Bai, Haochen Tang, Xiang Kong, Lu Zou, Qinghua Zheng, Yingxin Wang, Yan Zhao, Baorui Liu, Fanyan Meng, Juan Du

  • June 29, 2026

Related Content

N4-acetylcytidine modification bridges metabolic reprogramming and immune evasion in cancer: mechanisms and therapeutic implications

Risk of lymph-node metastasis in early onset T1 colorectal cancer: a systematic review and meta-analysis

Endoscopic and histopathological phenotypes of early gastric neoplasia: toward an integrative host-response framework